Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ACAD 
ACADIA Pharmaceuticals Inc (ACAD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/11/2025: ACAD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -0.77% | Avg. Invested days 42 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/11/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.43B USD | Price to earnings Ratio 10.72 | 1Y Target Price 25.11 |
Price to earnings Ratio 10.72 | 1Y Target Price 25.11 | ||
Volume (30-day avg) 1780671 | Beta 0.54 | 52 Weeks Range 13.40 - 20.68 | Updated Date 04/13/2025 |
52 Weeks Range 13.40 - 20.68 | Updated Date 04/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.36 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 23.64% | Operating Margin (TTM) 2.69% |
Management Effectiveness
Return on Assets (TTM) 5.44% | Return on Equity (TTM) 38.89% |
Valuation
Trailing PE 10.72 | Forward PE 42.73 | Enterprise Value 1727778577 | Price to Sales(TTM) 2.54 |
Enterprise Value 1727778577 | Price to Sales(TTM) 2.54 | ||
Enterprise Value to Revenue 1.8 | Enterprise Value to EBITDA 17.25 | Shares Outstanding 166788992 | Shares Floating 114380229 |
Shares Outstanding 166788992 | Shares Floating 114380229 | ||
Percent Insiders 0.46 | Percent Institutions 100.45 |
Analyst Ratings
Rating 3.89 | Target Price 24.95 | Buy 6 | Strong Buy 6 |
Buy 6 | Strong Buy 6 | ||
Hold 6 | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
ACADIA Pharmaceuticals Inc
Company Overview
History and Background
ACADIA Pharmaceuticals Inc. was founded in 1993. Initially focused on drug discovery, it has evolved into a commercial-stage biopharmaceutical company focused on central nervous system disorders.
Core Business Areas
- Commercialization: Focuses on the commercialization of NUPLAZID (pimavanserin) for Parkinsonu2019s disease psychosis.
- Research and Development: Dedicated to research and development of therapies for other CNS disorders.
Leadership and Structure
The leadership team is headed by the CEO. The organizational structure is typical of a biopharmaceutical company, with research, development, commercial, and administrative divisions.
Top Products and Market Share
Key Offerings
- NUPLAZID (pimavanserin): NUPLAZID is a selective serotonin inverse agonist and antagonist preferentially targeting 5-HT2A receptors. It is approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. NUPLAZID holds nearly 100% market share in PDP. Competitors include off-label use of antipsychotics like quetiapine and clozapine.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and significant competition. The CNS market is driven by unmet needs in areas like psychosis, dementia-related psychosis, and depression.
Positioning
ACADIA is positioned as a leader in the treatment of Parkinson's disease psychosis (PDP). Its competitive advantage lies in its first-mover status and established clinical data for NUPLAZID.
Total Addressable Market (TAM)
The TAM for PDP is estimated to be billions of dollars, with a significant unmet need. Acadia is well-positioned to address this need with NUPLAZID, with the ability to continue to expand into other CNS conditions.
Upturn SWOT Analysis
Strengths
- First-mover advantage in PDP
- Strong clinical data for NUPLAZID
- Dedicated sales and marketing team
- Established relationships with key opinion leaders
Weaknesses
- Sole reliance on NUPLAZID
- High marketing and sales expenses
- Risk of generic competition
- Limited pipeline
Opportunities
- Expansion of NUPLAZID into other indications (e.g., dementia-related psychosis)
- Acquisition or licensing of new assets
- Geographic expansion
- Advancements in neurology/psychiatry care.
Threats
- Regulatory setbacks
- Competition from new therapies
- Patent challenges
- Pricing pressures
Competitors and Market Share
Key Competitors
- TEVA
- MYL
- ABBV
Competitive Landscape
Acadia's advantage is in NUPLAZID's proven efficacy and first-mover status, but they lack product diversity compared to larger pharmaceutical companies.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is tied to NUPLAZID sales, indicating reliance on product performance. Additional details requires data.
Future Projections: Future growth projections depends on label expansions and new product approvals.
Recent Initiatives: Recent initiatives include trials for dementia-related psychosis and partnerships to expand the pipeline.
Summary
ACADIA Pharmaceuticals is a mid-sized biopharmaceutical company with a novel treatment for Parkinsonu2019s disease psychosis. While it has an advantage with NUPLAZID, its reliance on a single product and limited pipeline requires that it expand its future growth. Competition within the industry, regulatory setbacks, and other threats must be watched closely. Overall, the company has strong advantages with NUPLAZID with plenty of potential in CNS disorders
Similar Companies
ALKS
Alkermes Plc
ALKS
Alkermes Plc
JAZZ
Jazz Pharmaceuticals PLC
JAZZ
Jazz Pharmaceuticals PLC
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Market research reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data is estimated. Market share data is approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ACADIA Pharmaceuticals Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2004-05-27 | CEO & Director Ms. Catherine E. Owen Adams | ||
Sector Healthcare | Industry Biotechnology | Full time employees 653 | Website https://www.acadia.com |
Full time employees 653 | Website https://www.acadia.com | ||
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin which completed Phase III clinical trial to treat the negative symptoms of schizophrenia; ACP-101, which completed phase III clinical trial for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 that completed phase II clinical trial for the treatment of Alzheimer's disease psychosis and Lewy Body Dementia with psychosis; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; ACP-211 that is in phase I clinical trial for the treatment of treatment-resistant depression; ACP-2591 that is in Phase I development for Rett syndrome and Fragile X syndrome; and ACP-271, a GPR88 agonist used in evaluation of neurology and is in the IND-enabling stage. The company has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.